Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30005976 | 1.00 | RXFP1 (0.50) | RXFP1HDAC1CA1CA2CA9 | |
| SCHEMBL422893 | 0.85 | CA1 (0.58) | RXFP1HDAC1CA1CA2CA9 | |
| SCHEMBL30559973 | 0.85 | CA1 (0.58) | RXFP1HDAC1CA1CA2CA9 | |
| SCHEMBL1704181 | 0.83 | ALDH1A1 (0.44) | HDAC1HDAC6SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL20560249 | 0.81 | ALOX15 (0.43) | HDAC1HDAC6SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL30748254 | 0.81 | SMN1; SMN2 (0.55) | HDAC1CA1CA2CA9HDAC6 | |
| SCHEMBL8955980 | 0.81 | SMN1; SMN2 (0.55) | HDAC1CA1CA2CA9HDAC6 | |
| SCHEMBL3715354 | 0.81 | ALDH1A1 (0.58) | RXFP1HDAC1CA1CA2CA9 | |
| SCHEMBL28355716 | 0.81 | KMT2A (0.46) | SMN1; SMN2GAAALDH1A1POLBMEN1 | |
| SCHEMBL1282557 | 0.81 | PDK1 (0.45) | CA1CA2CA9GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115305-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-04-30 | — | — | US | disclosed |
| US-12539336-B2 | Antibody, linkers, payload, conjugates and applications thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2026-02-03 | — | — | US | disclosed |
| US-20250387505-A1 | ANTI-FGFR3 ANTIBODY CONJUGATE AND MEDICAL USE THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| US-20250064953-A1 | Antibody, Linkers, Payload, Conjugates and Applications Thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2025-02-27 | — | — | US | disclosed |
| US-20250064957-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2025-02-27 | — | — | US | disclosed |
| EP-4480957-A2 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | Genequantum Healthcare (Suzhou) Co., Ltd. (CN) | 2024-12-25 | — | — | EP | disclosed |
| US-20240327416-A1 | Further Substituted Triazolo Quinoxaline Derivatives | GRUENENTHAL GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
| EP-4211145-B1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024002154-A9 | ANTI-FGFR3 ANTIBODY CONJUGATE AND MEDICAL USE THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2024-07-18 | — | — | WO | disclosed |
| CN-117279932-B | Esatitecan derivatives and linker-carriers and conjugates thereof | 启德医药科技（苏州）有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-7517906-B2 | Dimeric IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517906-B2 | Dimeric IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517906-B2 | Dimeric IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| CN-101128425-A | Dimeric IAP inhibitors | TETRALOGIC PHARMACEUTICALS (US) | 2008-02-20 | — | — | CN | disclosed |
| WO-2008014263-A2 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2008-01-24 | — | — | US | disclosed |
| EP-1851200-A2 | DIMERIC IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060194741-A1 | Dimeric IAP inhibitors | MEDIVIR AB (SE) | 2006-08-31 | — | — | US | disclosed |
| WO-2006091972-A2 | DIMERIC IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539336-B2 | Antibody, linkers, payload, conjugates and applications thereof | IGLV6-57, IGSF11, VSIG8 | RXFP1 813/4885HDAC1 4881/4885CA1 4764/4885 |
| US-20250064953-A1 | Antibody, Linkers, Payload, Conjugates and Applications Thereof | CD47, FCGR2A, CD22 | RXFP1 2412/4885HDAC1 3472/4885CA1 2466/4885 |
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | BIRC2, BIRC7, BIRC8 | RXFP1 3282/4885HDAC1 1560/4885CA1 2399/4885 |
| US-20260115305-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | CLTB, DCLRE1A, FCGRT | RXFP1 603/4885HDAC1 692/4885CA1 482/4885 |
| US-20240327416-A1 | Further Substituted Triazolo Quinoxaline Derivatives | NR3C1, GRK5, NR3C2 | RXFP1 1189/4885HDAC1 785/4885CA1 3720/4885 |
| US-20060194741-A1 | Dimeric IAP inhibitors | BIRC2, BIRC3, BIRC5 | RXFP1 3290/4885HDAC1 911/4885CA1 1495/4885 |
| US-20250387505-A1 | ANTI-FGFR3 ANTIBODY CONJUGATE AND MEDICAL USE THEREOF | FGFR3, IGSF11, IDUA | RXFP1 669/4885HDAC1 4291/4885CA1 2117/4885 |
| US-20250064957-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | XPOT, ENGASE, ENTPD8 | RXFP1 1486/4885HDAC1 1127/4885CA1 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.